Tykerb is a brand name of lapatinib, approved by the FDA in the following formulation(s):
TYKERB (lapatinib ditosylate - tablet; oral)
Manufacturer: SMITHKLINE BEECHAM
Approval date: March 13, 2007
Strength(s): EQ 250MG BASE [RLD]
Has a generic version of Tykerb been approved?
No. There is currently no therapeutically equivalent version of Tykerb available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tykerb. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
Patent 6,391,874
Issued: May 21, 2002
Inventor(s): George Stuart; Cockerill & Malcolm Clive; Carter & Stephen Barry; Guntrip & Kathryn Jane; Smith
Assignee(s): SmithKline Beecham Corporation
Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis, or a salt or solvate thereof; wherein X is N or CH; Y is a group W(CH2), (CH2)W, or W, in which W is O, S(O)m wherein m is 0, 1 or 2, or NRa wherein Ra is hydrogen or a C1-8 alkyl group; R1 represents a phenyl group or a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S(O)m, wherein m is as defined above, with the provisos that the ring does not contain two adjacent O or S(O)m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R1 being optionally substituted by one or more R3;groups; P=0 to 3; U, R2, R3 are as defined in the application.Patent expiration dates:
- July 11, 2017✓✓✓
- July 11, 2017
Heterocyclic compounds
Patent 6,713,485
Issued: March 30, 2004
Inventor(s): Malcolm Clive; Carter & George Stuart; Cockerill & Stephen Barry; Guntrip & Karen Elizabeth; Lackey & Kathryn Jane; Smith
Assignee(s): SmithKline Beecham Corporation
The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.Patent expiration dates:
- September 29, 2020✓✓✓
- September 29, 2020
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Patent 6,727,256
Issued: April 27, 2004
Inventor(s): Malcolm Clive; Carter & George Stuart; Cockerill & Stephen Barry; Guntrip & Karen Elizabeth; Lackey & Kathryn Jane; Smith
Assignee(s): SmithKline Beecham Corporation
Substituted heteroaromatic compounds of formula (I), wherein X is N or CH; Y is CR1 and V is N; or Y is N and V is CR1; or Y is CR1 and V is CR2; or Y is CR2 and V is CR1; R1 represents a group CH3SO2CH2CH2NHCH2—Ar—, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C1-4alkyl or C1-4alkoxy groups; R2 is selected from the group comprising hydrogen, halo, hydroxy, C1-4alkyl, C1-4alkoxy, C1-4alkylamino and di[C1-4alkyl]amino; U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R3 group and optionally substituted by at least one independently selected R4 group; R3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl, or R3 represents trihalomethylbenzyl or trihalomethylbenzyloxy; or R3 represents a group of formula (a) wherein each R5 is independently selected from halogen, C1-4alkyl, C1-4alkoxy; and n is 0 to 3; each R4 is independently hydroxy, halogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, amino, C1-4alkylamino, di[C1-4alkyl]amino, C1-4alkylthio, C1-4alkylsulphinyl, C1-4alkylsulphonyl, C1-4alkylcarbonyl, carboxy, carbamoyl, C1-4alkoxycarbonyl, C1-4alkanoylamino, N-(C1-4alkyl)carbamoyl, N,N-di(C1-4alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.Patent expiration dates:
- January 8, 2019✓✓✓
- January 8, 2019
Heterocyclic compounds
Patent 6,828,320
Issued: December 7, 2004
Inventor(s): George Stuart; Cockerill & Malcolm Clive; Carter & Stephen Barry; Guntrip & Kathryn Jane; Smith
Assignee(s): SmithKline Beecham Corporation
Substituted heteroaromatic compounds, and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.Patent expiration dates:
- July 11, 2017✓
- July 11, 2017
Quinazoline ditosylate salt compounds
Patent 7,157,466
Issued: January 2, 2007
Inventor(s): McClure; Michael Scott & Osterhout; Martin Howard & Roschangar; Frank & Sacchetti; Mark Joseph
Assignee(s): SmithKline Beecham (Cork) Limited
Ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorde4rs characterized by aberrant erbB family PTK activity.Patent expiration dates:
- November 19, 2021✓✓
- November 19, 2021
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 13, 2012 - NEW CHEMICAL ENTITY
- January 29, 2013 - FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
See also...
- Tykerb Consumer Information (Drugs.com)
- Tykerb Consumer Information (Wolters Kluwer)
- Tykerb Consumer Information (Cerner Multum)
- Tykerb Advanced Consumer Information (Micromedex)
- Tykerb AHFS DI Monographs (ASHP)
- Lapatinib Consumer Information (Wolters Kluwer)
- Lapatinib Consumer Information (Cerner Multum)
- Lapatinib Advanced Consumer Information (Micromedex)
- Lapatinib Ditosylate AHFS DI Monographs (ASHP)
No comments:
Post a Comment